Strontium ranelate for preventing and treating postmenopausal osteoporosis
O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY
Published in Cochrane Database of Systematic Reviews
Methodology
Cochrane review pooling randomized placebo-controlled trials of strontium ranelate in postmenopausal women.
Key Findings
Pooled data confirmed reductions in vertebral and nonvertebral fractures, with increased risk of diarrhoea and venous thromboembolism.
Conclusions
Strontium ranelate reduces fractures but carries thromboembolic and gastrointestinal risks.
Limitations
Evidence limited to the ranelate salt; no data on over-the-counter strontium citrate.
Supplements Studied
Strontium ranelate reduces fractures but carries thromboembolic and gastrointestinal risks.
Outcomes Measured
Evidence limited to the ranelate salt; no data on over-the-counter strontium citrate.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.